ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sodium zirconium cyclosilicate

Also written as “Sodium Zirconium Cyclosilicate”, “Sodium Zirconium Cyclosilicate (SZC)” and “Sodium zirconium cyclosilicate”.

Its studies are mostly in Hyperkalemia · Renal Insufficiency, Chronic · Heart Failure, led by AstraZeneca.

Drug pageSodium zirconium cyclosilicate: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 16, 202020 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca202 open or runningphase 4since Dec 16, 2020Mar 12, 2014Oct 30, 2027phase 4 · NCT07944378

Also a collaborator on its studies: Parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Mar 12, 2014.

  1. Sep 26, 2017Phase 3 study in HyperkalemiaNCT03303521 · 196 enrolled · United States, Japan, Russian Federation and more
  2. Oct 23, 2017Phase 2 study in HyperkalemiaNCT03337477 · 70 enrolled · United States, Denmark, Italy and more
  3. Mar 29, 2018Phase 2 study in Heart FailureNCT03532009 · 182 enrolled · United States, Brazil, Bulgaria and more
  4. Apr 16, 2018Phase 3 study in HyperkalemiaNCT03528681 · 270 enrolled · China, India
  5. Nov 22, 2018Phase 3 study in HyperkalemiaNCT03813407 · 140 planned · United States, Brazil, Canada and more
  6. Jan 2, 2020Phase 3 study in HyperkalemiaNCT04217590 · 134 enrolled · China
  7. Dec 16, 2020Phase 4 study in HyperkalemiaNCT04676646 · 366 enrolled · United States, Brazil, Canada and more
  8. Dec 22, 2020Phase 3 study in HyperkalemiaNCT04727528 · 39 enrolled · United States, Puerto Rico
  9. Mar 5, 2021Phase 1 study in HyperkalemiaNCT04788641 · 62 enrolled · Germany
  10. Apr 8, 2021Phase 3 study in HyperkalemiaNCT04847232 · 2,690 enrolled · United States, Argentina, Austria and more
  11. Jun 16, 2021Phase 4 study in HyperkalemiaNCT04997161 · 3 enrolled · United States
  12. Sep 1, 2021Phase 3 study in Renal Insufficiency, ChronicNCT05056727 · 1,112 enrolled · United States, Argentina, Brazil and more
  13. Feb 23, 2022Phase 4 study in HyperkalemiaNCT05347693 · 186 enrolled · Belgium, France, Italy and more
  14. Nov 3, 2026Phase 4 study in HyperkalemiaNCT07944378 · 120 planned · India

Ahead

  1. Oct 30, 2027Primary completion: phase 4 study in HyperkalemiaNCT07944378
  2. Feb 21, 2030Primary completion: phase 3 study in HyperkalemiaNCT03813407

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07944378Hyperkalemia · India4RecruitingOct 30, 2027120
NCT05347693Hyperkalemia · Belgium, France, Italy and more4CompletedDec 10, 2024186
NCT05056727Renal Insufficiency, Chronic · United States, Argentina, Brazil and more3TerminatedFeb 7, 20241,112
NCT04997161Hyperkalemia · United States4TerminatedNov 17, 20213
NCT04847232Hyperkalemia · United States, Argentina, Austria and more3TerminatedMar 7, 20242,690
NCT04788641Hyperkalemia · Germany1CompletedSep 16, 202162
NCT04727528Hyperkalemia · United States, Puerto Rico3TerminatedSep 14, 202239
NCT04676646Hyperkalemia · United States, Brazil, Canada and more4CompletedJul 15, 2024366
NCT04217590Hyperkalemia · China3CompletedJan 3, 2022134
NCT03813407Hyperkalemia · United States, Brazil, Canada and more3RecruitingFeb 21, 2030140
NCT03528681Hyperkalemia · China, India3CompletedSep 15, 2022270
NCT03532009Heart Failure · United States, Brazil, Bulgaria and more2TerminatedMay 22, 2020182
NCT03337477Hyperkalemia · United States, Denmark, Italy and more2CompletedDec 21, 201870
NCT03303521Hyperkalemia · United States, Japan, Russian Federation and more3CompletedNov 7, 2018196
NCT03283267Hyperkalemia · Hong Kong1CompletedNov 23, 201722
NCT03127644Hyperkalemia · Japan3CompletedFeb 23, 2018103
NCT02875834Hyperkalemia · Japan, Korea, Republic of, Russian Federation and more3CompletedFeb 14, 2018267
NCT02163499Hyperkalemia · United States, Australia, Germany and more3CompletedNov 30, 2016751
NCT02107092Hyperkalemia · United States, Australia, South Africa3CompletedJul 31, 2015123
NCT02088073Hyperkalemia · United States, Australia, South Africa3CompletedAug 31, 2014258

How it is read

Names in the registry

  • “Sodium Zirconium Cyclosilicate”, 5 entries
  • “Sodium Zirconium Cyclosilicate (SZC)”, 4 entries
  • “Sodium zirconium cyclosilicate”, 3 entries
  • “Sodium Zirconium Cyclosilicate (ZS) 10g”, 3 entries
  • “Sodium Zirconium Cyclosilicate (ZS) 5g”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.